E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/25/2017 in the Prospect News Structured Products Daily.

New Issue: Morgan Stanley prices $9.34 million contingent income autocallables linked to ETFs

By Angela McDaniels

Tacoma, Wash., Sept. 25 – Morgan Stanley Finance LLC priced $9.34 million of contingent income autocallable securities due Sept. 30, 2019 linked to the worst performing of the SPDR S&P Biotech exchange-traded fund, the Financial Select Sector SPDR fund and the Technology Select Sector SPDR fund, according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by Morgan Stanley.

Each quarter, the notes pay a contingent coupon at an annual rate of 13.47% if each fund closes at or above its downside threshold level, 75% of its initial share price, on the determination date for that quarter.

The notes will be automatically called at par if each fund closes at or above its initial share price on any quarterly determination date.

The payout at maturity will be par unless the final share price of any ETF is less than its downside threshold level, in which case investors will be fully exposed to the decline of the worst-performing ETF.

Morgan Stanley & Co. LLC is the agent.

Issuer:Morgan Stanley Finance LLC
Guarantor:Morgan Stanley
Issue:Contingent income autocallable securities
Underlying ETFs:SPDR S&P Biotech ETF (Symbol: XBI), Financial Select Sector SPDR fund (Symbol: XLF) and Technology Select Sector SPDR fund (Symbol: XLK)
Amount:$9.34 million
Maturity:Sept. 30, 2019
Coupon:13.47%, payable quarterly if each fund closes at or above downside threshold level on determination date for that quarter
Price:Par
Payout at maturity:If each fund finishes at or above downside threshold level, par; if final level of any fund is less than downside threshold level, full exposure to decline of worst-performing fund
Call:Automatically at par if each fund closes at or above initial share price on any quarterly determination date
Initial share prices:$84.59 for biotech fund, $25.46 for financial fund and $58.49 for technology fund
Downside thresholds:$63.443 for biotech fund, $19.095 for financial fund and $43.868 for technology fund; 75% of initial share prices
Pricing date:Sept. 21
Settlement date:Sept. 26
Agent:Morgan Stanley & Co. LLC
Fees:1.75%
Cusip:61768CQZ3

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.